GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
GT Biopharma, Inc. filed a Form 8-K dated September 22, 2026, under Item 8.01, “Other Events.” The filing concerns the company’s compliance with Nasdaq’s minimum bid price requirement for continued listing.
Key Financial Metrics
The filing does not provide revenue, profitability, cash flow, margin, debt, liquidity, or other operating and financial metrics.
Material Changes
- On November 20, 2025, Nasdaq notified the company that its common stock had closed below $1.00 per share for 30 consecutive business days, resulting in noncompliance with Nasdaq Listing Rule 5550(a)(2).
- On May 20, 2026, Nasdaq granted the company an additional 180-calendar-day compliance period through November 16, 2026.
- On September 22, 2026, Nasdaq notified the company that it had regained compliance because its common stock maintained a closing bid price above $1.00 per share for at least 10 consecutive business days.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The principal disclosed risk was potential Nasdaq delisting arising from failure to satisfy the minimum bid price requirement; that deficiency was reported as cured as of September 22, 2026. The company is fully remote and does not maintain a principal executive office.
Important Facts to Verify
- Confirm Nasdaq’s continuing listing status and whether any other listing deficiencies remain.
- Verify the dates and duration of the closing bid-price compliance period.
- Review subsequent filings for capital raises, reverse stock splits, liquidity developments, or other actions that could affect listing compliance.
- Note that the filing date is September 22, 2026, while the signature is dated September 25, 2026.